MAGNESIUM METALLICUM
Concussion Post Syndrome
Corewell Health SouthSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Concussion Post Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Montefiore Medical Center | Phase 4 | BB |
Oxygen Essentia Health | Phase 2 | B |
Same molecule, other indications
MAGNESIUM METALLICUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →